JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Gesloten

SectorGezondheidszorg

80.6 -0.59

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

80.28

Max

81.54

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.8M -87M
Verkoop	96K 2.9M
Winstmarge	-3,041.294
Werknemers	238
EBITDA	-5.8M -85M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+43.65% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.4M 7.1B
Vorige openingsprijs	81.19
Vorige sluitingsprijs	80.6

Nieuwssentiment

By Acuity

38%

62%

137 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

28.34 / 33.56 Steun & Weerstand

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

43.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 120.08 USD 43.65%

Hoogste 140 USD

Laagste 100 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Kymera Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

28.34 / 33.56Steun & Weerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

137 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.